

GenVoy-ILM™ T Cell Kit for mRNA on NanoAssemblr® Spark™


Rethink Cell Therapy
with Lipid Nanoparticles



Rethink T Cell Gene Delivery With GenVoy-ILM T Cell Kit for mRNA


Lipid Nanoparticle (LNP) based technology enables researchers to establish a clinically relevant, scalable method for *ex vivo* gene delivery to advance the development of cell therapies.

The GenVoy-ILM™ T Cell Kit for mRNA is an LNP reagent mix. This kit is optimized for the delivery of mRNA into activated primary human T cells using mRNA-LNPs formulated on the NanoAssemblr® Spark™ instrument and cartridges. It can be used at various stages of cell therapy research and development from discovery to preclinical across the NxGen™ microfluidics instrument platform.




Why use the GenVoy-ILM T Cell Kit for mRNA for *ex vivo* gene delivery into T cells?


- Greater Proportion of Engineered T Cells
- Uniform Cellular Protein Expression
- Tunable Biological Outcomes
- Highly Viable T Cells
- A Simple Protocol with Minimal T Cell Manipulation



mRNA-LNPs leverage endogenous cellular uptake mechanisms




1 GenVoy-ILM contains an ionizable cationic lipid, which at low pH mediates efficient encapsulation of mRNA



2 The mRNA-lipid core is surrounded by helper lipids, cholesterol and stabilizers to form the mRNA-LNP




3 Once formed, mRNA-LNP are neutral at physiological pH which eliminates a main source of toxicity present in other mRNA delivery methods



4 mRNA-LNP mimic low density lipoproteins (LDL) and are then taken up through receptor-mediated endocytosis



5 Once in the endosome, ionizable lipids in mRNA-LNP respond to low pH and become cationic




6 The cationic lipids in the mRNA-LNP interact with anionic lipids in the endosome and release the mRNA into the cytoplasm

GenVoy-ILM T Cell Kit for mRNA: A New Way to Deliver mRNA *Ex Vivo*

Greater Proportion of Engineered T Cells


Delivering mRNA into activated human primary T cells using the kit leads to a higher proportion of engineered T cells, making it a more potent gene delivery method than electroporation.



Transfection efficiency was measured by protein expression via flow cytometry at 24 and 48 hours post treatment. Electroporation (EP) was performed by following the manufacturer's protocol, and LNP treatment was performed following the GenVoy-ILM T Cell Kit for mRNA on Spark™ protocol. Untreated cells (UT) were used as control. **p<0.01, ****p<0.0001 by one-way ANOVA.

Uniform Cellular Protein Expression


Engineering human primary T cells using the GenVoy-ILM T Cell Kit for mRNA results in highly uniform protein expression across the treated cell population.



Representative mean fluorescence intensity (MFI) plots of cell surface protein expression were generated using flow cytometry at 24 and 48 hours post treatment. Electroporation was performed by following manufacturer's protocol. Untreated cells (UT) were used as control.

Highly Viable T Cells

Activated human primary T cells remain highly viable after *ex vivo* gene delivery using the kit.




Cell viability was measured via flow cytometry at 24 and 48 hours post treatment. Electroporation (EP) was performed by following the manufacturer's protocol, and LNP treatment was performed following the T Cell Kit for mRNA on Spark™ protocol. Untreated cells (UT) were used as control. ****p<0.0001 by one-way ANOVA.

GenVoy-ILM T Cell Kit for mRNA: A New Way to Deliver mRNA *Ex Vivo* (Continued)

Tunable Biological Outcomes

Achieve an ideal balance between transfection efficiency, protein expression, and cell viability in a dose-dependent manner.





CD19 CAR transfection efficiency and cell viability were measured via flow cytometry 48 hours post treatment. Cells were treated with CD19 CAR mRNA at the indicated doses. Untreated cells (UT) were used as control.

**p<0.01 by one-way ANOVA.

Functional Tumor Cell Killing

CAR T cells engineered using the GenVoy-ILM T Cell Kit for mRNA effectively kill CD19+ tumor cells in a dose-dependent manner.





Tumor cell viability was assessed using flow cytometry. Lysis was determined by normalizing cell death in co-culture to controls.

p<0.001, *p<0.0001 by one-way ANOVA.

A New Method to Advance T Cell Therapy

A simple protocol with minimal T cell manipulation




Advantages of GenVoy-ILM T Cell Kit for mRNA



**GREATER PROPORTION
OF ENGINEERED CELLS**



HIGH CELL VIABILITY




**UNIFORM CELLULAR
PROTEIN EXPRESSION**



**TUNABLE BIOLOGICAL
OUTCOMES**


Lipid Nanoparticles Empower Genetic Medicine Development

Precision NanoSystems' Genetic Medicine Toolkit uses the GenVoy LNP Delivery Platform to support the rapid and cost-effective development of genetic vaccines, gene therapies and cell therapies. PNI's technology platforms and expertise enable researchers to translate biological insights into treatments for areas of unmet need such as infectious disease, rare disease and cancer.



Lipid Nanoparticles Are a Clinically Validated Delivery Technology

LNPs have been clinically validated to successfully deliver RNA, from the first approved siRNA-LNP Onpattro®, to mRNA-LNP COVID-19 vaccines from Moderna and Pfizer/BioNTech.



First RNA-LNP Vaccine for Widespread Use

Pfizer/BioNTech developed and manufactured an mRNA-LNP vaccine for COVID-19 in less than a year and was the first approved for emergency use by the FDA.

Polack et al. NEJM. 2020.

RNA-LNP Drugs Can Treat Rare Disease

In 2018, Alnylam received authorization for Patisiran, the first siRNA-LNP drug to be offered for commercial use, to treat hATTR amyloidosis.


Adams et al. NEJM. 2018.

RNA-LNP Vaccines Are Rapidly Developed

Moderna was the first mRNA-LNP COVID-19 vaccine, starting human clinical trials in 66 days of viral sequencing, and was approved by the FDA within a year.

Baden et al. NEJM. 2020.

Ordering Information

T CELL KIT FOR mRNA		PRODUCT NUMBER
	GenVoy-ILM™ T Cell Kit for mRNA	1000701
	GenVoy-ILM™ T Cell Kit for mRNA with Spark Cartridges	1000683
INSTRUMENTS, CARTRIDGES AND ACCESSORIES		
	NanoAssemblr® Spark™	NIS0001
	NanoAssemblr® Spark™ Cartridges (20 pack, 80 pack)	NIS0009 NIS0013

A Powerful Method to Engineer T Cells



About Precision NanoSystems

PNI is a global leader ushering in the next wave of genetic medicines in infectious diseases, cancer and rare diseases. We work with the world's leading drug developers to understand disease and create the therapeutics and vaccines that will define the future of medicine. PNI offers proprietary technology platforms and comprehensive expertise to enable researchers to translate disease biology insights into non-viral genetic medicines.

Precision NanoSystems Inc.
50 - 655 West Kent Ave. N.,
Vancouver, BC, V6P 6T7
Canada

Precision NanoSystems Inc.
395 Oyster Point Boulevard, Suite 145
South San Francisco, CA, 94080
USA

phone: 1-888-618-0031
info@precision-nano.com

precisionnanosystems.com

Precision Nanosystems Europe:
Two Snowhill Road
Birmingham, UK. B4 6WR

Precision Nanosystems APAC:
10 Anson Road #12-#14
International Plaza
Singapore 079903

Document ID: tcellkitmrnaspark-BR-1121

For research use only. Not for use in humans or animals for diagnostic or therapeutic uses. Copyright © Precision NanoSystems Inc. 2021 All rights reserved. Create Translative Medicines™ and NanoAssemblr® are trademarks of Precision NanoSystems Inc.